Cardiac rehabilitation may influence leptin and VEGF A crosstalk in patients after acute coronary syndrome

Damian Skrypnik, Katarzyna Skrypnik, Joanna Suliburska, Paweł Bogdański, Damian Skrypnik, Katarzyna Skrypnik, Joanna Suliburska, Paweł Bogdański

Abstract

Leptin, a well-proven cardiovascular risk factor, influences vascular endothelial growth factor A (VEGF A) synthesis via hypoxia-inducible factor 1 alpha (HIF-1A), nuclear factor kappa-light-chain-enhancer of activated B cells (NfkB) and NILCO (Notch, interleukin 1 [IL1] and leptin cross-talk outcome) pathways. This study aimed to investigate the influence of cardiac rehabilitation (CR) on HIF-1A, NfkB and NILCO dependent leptin and VEGF A cross-talk in patients after acute coronary syndrome (ACS). Fifty post-ACS patients underwent a 2-week CR programme (study group S) and were compared to 50 post-ACS subjects who did not undergo CR (control group K). In group S, at baseline and at completion and in group K once, anthropometric, body composition, blood pressure and heart rate measurements were taken and blood sampling was performed. Serum levels of leptin, VEGF A, VEGF receptor 2 (VEGF R2), HIF-1A, NfkB, interleukin 1-alpha (IL1-alpha) and Notch 1 were determined. In group S, serum VEGF A levels increased while leptin, HIF-1A and VEGF R2 levels decreased and completion but not baseline serum leptin correlated positively with serum VEGF A. Also, serum completion VEGF A correlated positively with NfkB and HIF-1A in group S. Correlation analysis in group S confirmed the significant role of the NILCO pathway in the regulation of VEGF A serum levels mediated by HIF-1A and NfkB. CR may induce the predomination of the NILCO pathway interacting with HIF-1A and NfkB over leptin canonical and non-canonical signalling pathways in the leptin influence on VEGF A in post-ACS patients.Trial registration: ClinicalTrials.gov ID: NCT03935438. The CARDIO-REH randomised study.

Conflict of interest statement

The authors declare no competing interests.

© 2022. The Author(s).

Figures

Figure 1
Figure 1
The study flow diagram.

References

    1. Khan MA, et al. Global epidemiology of ischemic heart disease: Results from the global burden of disease study. Cureus. 2020;12:e9349.
    1. Zhao Z, Winget M. Economic burden of illness of acute coronary syndromes: Medical and productivity costs. BMC Health Serv. Res. 2011;11:35.
    1. Halmai, E. J. Quality and outcome measures for medical rehabilit. In Braddom’s Rehabilitation Care: A Clinical Handbook 39–43 (Elsevier-Health Sciences Division, 2018).
    1. Piotrowicz R. Rekomendacje w zakresie realizacji kompleksowej rehabilitacji kardiologicznej (Recommendations for the implementation of comprehensive cardiac rehabilitation) Polish Cardiac Society; AsteriaMed; Gdańsk; 2017.
    1. Yang X, et al. Effects of exercise-based cardiac rehabilitation in patients after percutaneous coronary intervention: A meta-analysis of randomized controlled trials. Sci. Rep. 2017;7:44789.
    1. JCS Joint Working Group Guidelines for rehabilitation in patients with cardiovascular disease (JCS 2012): Digest version. Circ. J. 2014;78:2022–2093.
    1. Fox K, et al. Guidelines on the management of stable angina pectoris: Executive summary—The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur. Heart J. 2006;27:1341–1381.
    1. So R, et al. Visceral adipose tissue volume estimated at imaging sites 5–6 cm above L4–L5 is optimal for predicting cardiovascular risk factors in obese Japanese men. Tohoku J. Exp. Med. 2012;227:297–305.
    1. Abu-Farha M, Behbehani K, Elkum N. Comprehensive analysis of circulating adipokines and hsCRP association with cardiovascular disease risk factors and metabolic syndrome in Arabs. Cardiovasc. Diabetol. 2014;13:1–10.
    1. Izquierdo AG, Crujeiras AB, Casanueva FF, Carreira MC. Leptin, obesity, and leptin resistance: Where are we 25 years later? Nutrients. 2019;11:2704.
    1. Wróblewski A, et al. Molecular insight into the interaction between epigenetics and leptin in metabolic disorders. Nutrients. 2019;11:1872.
    1. Farcaş AD, Rusu A, Stoia MA, Vida-Simiti LA. Plasma leptin, but not resistin, TNF-α and adiponectin, is associated with echocardiographic parameters of cardiac remodeling in patients with coronary artery disease. Cytokine. 2018;103:46–49.
    1. Sierra-Johnson J, et al. Relation of increased leptin concentrations to history of myocardial infarction and stroke in the United States population. Am. J. Cardiol. 2007;100:234–239.
    1. Puurunen VP, et al. Leptin predicts short-term major adverse cardiac events in patients with coronary artery disease. Ann. Med. 2017 doi: 10.1080/07853890.2017.130167849,448-454.
    1. Khafaji HARH, Bener AB, Rizk NM, Al Suwaidi J. Elevated serum leptin levels in patients with acute myocardial infarction; Correlation with coronary angiographic and echocardiographic findings. BMC Res. Notes. 2012;5:1–8.
    1. Fujimaki S, Kanda T, Fujita K, Tamura J, Kobayashi I. The significance of measuring plasma leptin in acute myocardial infarction. J. Int. Med. Res. 2001;29:108–113.
    1. Morita Y, et al. Impact of adiponectin and leptin on long-term adverse events in Japanese patients with acute myocardial infarction. Results from the Nagoya Acute Myocardial Infarction Study (NAMIS) Circ. J. 2013;77:2778–2785.
    1. Roszkowska-Gancarz M, et al. Functional polymorphisms of the leptin and leptin receptor genes are associated with longevity and with the risk of myocardial infarction and of type 2 diabetes mellitus. Endokrynol. Pol. 2014;65:11–16.
    1. Sari İ, Habipoğlu S, Seydel GŞ, Erşan S, Güntürk İ. The effect of acute step-aerobic exercise on adiponectin and leptin levels in premenopausal women. J. Sports Med. Phys. Fitness. 2021;61:725–731.
    1. Cicchella A, Carluccio M, Scoditti E, Kaltsatou A, Massaro M. Leptin and exercise: An update. Gazz. Medica Ital. Arch. per le Sci. Mediche. 2020;179:468–473.
    1. Fedewa MV, Hathaway ED, Ward-Ritacco CL, Williams TD, Dobbs WC. The effect of chronic exercise training on leptin: A systematic review and meta-analysis of randomized controlled trials. Sports Med. 2018;48:1437–1450.
    1. Del Mar Roca-Rodríguez M, et al. Effects of exercise on inflammation in cardiac rehabilitation. Nutr. Hosp. 2015;31:2633–2640.
    1. Leptin, adiponectin, uric acid, cardiac rehabilitation—Order reprints #881654 | Medical Science and Technology. .
    1. Influence of exercise training on leptin levels in patients with stable coronary artery disease: A pilot study—PubMed. .
    1. Chen J, et al. VEGF amplifies transcription through ETS1 acetylation to enable angiogenesis. Nat. Commun. 2017;8:1–13.
    1. Tam J, et al. Blockade of VEGFR2 and not VEGFR1 can limit diet-induced fat tissue expansion: Role of local versus bone marrow-derived endothelial cells. PLoS ONE. 2009;4:e4974.
    1. Vural P, Kabaca G, Firat RD, Degirmecioglu S. Administration of selenium decreases lipid peroxidation and increases vascular endothelial growth factor in streptozotocin induced diabetes mellitus. Cell J. 2017;19:452–460.
    1. Zou J, et al. VEGF-A promotes angiogenesis after acute myocardial infarction through increasing ROS production and enhancing ER stress-mediated autophagy. J. Cell. Physiol. 2019;234:17690–17703.
    1. Braile M, et al. VEGF-A in cardiomyocytes and heart diseases. Int. J. Mol. Sci. 2020;21:1–18.
    1. Gagliardi JA, et al. Relationship between endothelial progenitor cells and vascular endothelial growth factor and its variation with exercise. Thromb. Res. 2016;137:92–96.
    1. Kourek C, et al. The acute and long-term effects of a cardiac rehabilitation program on endothelial progenitor cells in chronic heart failure patients: Comparing two different exercise training protocols. Int. J. Cardiol. Hear. Vasc. 2020;32:100702.
    1. Gonzalez-Perez RR, et al. Leptin upregulates VEGF in breast cancer via canonic and non-canonical signalling pathways and NFkappaB/HIF-1alpha activation. Cell. Signal. 2010;22:1350–1362.
    1. Guo S, Gonzalez-Perez RR. Notch, IL-1 and leptin crosstalk outcome (NILCO) is critical for leptin-induced proliferation, migration and VEGF/VEGFR-2 expression in breast cancer. PLoS ONE. 2011;6:e21467.
    1. Yang WH, et al. Leptin promotes VEGF-C production and induces lymphangiogenesis by suppressing miR-27b in human chondrosarcoma cells. Sci. Rep. 2016;6:1–10.
    1. Skrypnik D, Mostowska A, Jagodziński PP, Bogdański P. Association of rs699947 (−2578 C/A) and rs2010963 (−634 G/C) single nucleotide polymorphisms of the VEGF gene, VEGF-A and leptin serum level, and cardiovascular risk in patients with excess body mass: A case-control study. J. Clin. Med. 2020;9:469.
    1. Skrypnik D, et al. The effect of: Plantago major supplementation on leptin and VEGF-A serum levels, endothelial dysfunction and angiogenesis in obese women—A randomised trial. Food Funct. 2021;12:1708–1718.
    1. Fletcher GF, et al. Exercise standards for testing and training: A statement for healthcare professionals from the American Heart Association. Circulation. 2001;104:1694–1740.
    1. Gibbons RJ, et al. ACC/AHA 2002 guideline update for exercise testing: Summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to update the 1997 exercise testing guidelines) J. Am. Coll. Cardiol. 2002;40:1531–1540.
    1. Ferguson B. ACSM’s guidelines for exercise testing and prescription 9th ed 2014. J. Can. Chiropr. Assoc. 2014;58:328.
    1. Stanisz A. Przystępny kurs statystyki z zastosowaniem STAISTICA PL na przykładach z medycyny. Tom 3. Analizy wielowymiarowe. (StatSoft Polska, 2007).
    1. Takeji Y, et al. Differences in mortality and causes of death between STEMI and NSTEMI in the early and late phases after acute myocardial infarction. PLoS ONE. 2021;16:e0259268.
    1. Zeng R, Xu CH, Xu YN, Wang YL, Wang M. Association of leptin levels with pathogenetic risk of coronary heart disease and stroke: A meta-analysis. Arq. Bras. Endocrinol. Metabol. 2014;58:817–823.
    1. Yang N, Qin Q. Apolipoprotein J: A new predictor and therapeutic target in cardiovascular disease? Chin. Med. J. 2015;128:2530.
    1. Basati G, Razavi AE, Abdi S, Sarrafzedegan N. Association of plasma leptin, homocysteine and nitric oxide levels with the presence and unstability of coronary artery disease. Biomark. Med. 2014;8:405–412.
    1. Tsai JP, et al. Association of serum leptin levels with central arterial stiffness in coronary artery disease patients. BMC Cardiovasc. Disord. 2016;16:1–7.
    1. Feijóo-Bandín S, et al. 20 years of leptin: Role of leptin in cardiomyocyte physiology and physiopathology. Life Sci. 2015;140:10–18.
    1. Bigalke B, et al. High plasma levels of adipocytokines are associated with platelet activation in patients with coronary artery disease. Platelets. 2010;21:11–19. doi: 10.3109/09537100903377584.
    1. Stergiou GS, et al. 2021 European Society of Hypertension practice guidelines for office and out-of-office blood pressure measurement. J. Hypertens. 2021;39:1293–1302.
    1. Takahashi Y, Satoh M, Tabuchi T, Nakamura M. Prospective, randomized, single-blind comparison of effects of 6 months’ treatment with atorvastatin versus pravastatin on leptin and angiogenic factors in patients with coronary artery disease. Heart Vessels. 2012;27:337–343.
    1. Abd Alkhaleq H, et al. Leptin modulates gene expression in the heart, cardiomyocytes and the adipose tissue thus mitigating LPS-induced damage. Exp. Cell Res. 2021;404:112647.
    1. Zhou W, Guo S, Gonzalez-Perez RR. Leptin pro-angiogenic signature in breast cancer is linked to IL-1 signalling. Br. J. Cancer. 2011;104:128.
    1. Erkasap N, et al. Role of Notch, IL-1 and leptin expression in colorectal cancer. Exp. Ther. Med. 2021;21:1–11.
    1. Guo S, Liu M, Gonzalez-Perez RR. Role of Notch and its oncogenic signaling crosstalk in breast cancer. Biochim. Biophys. Acta. 2011;1815:197.
    1. European Society of Cardiology 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH) Eur. Heart J. 2018;39:3021–3104.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera